Ebola GP1 Surface Protein Humanized Antibody (Ansuvimab) | A2298

This research-grade biosimilar is a humanized antibody that targets the envelope glycoprotein of Ebola virus. Infection with pathogenic filoviruses such as Ebola can cause severe hemorrhagic fever in humans, with fatality rates as high as 90%. The envelope glycoprotein complex is responsible for the viral entry into host cells via binding to host surface receptors. The most successful methods for treatment of Ebola involve the targeting of its surface glycoproteins. The original humanized monoclonal antibody was shown to successfully treat Ebola patients, with improved patient survival and more efficient viral clearance.

A2298 | Ebola GP1 Surface Protein Humanized Antibody (Ansuvimab) DataSheet

Antibody Target: Envelope glycoprotein of Ebola virus

Target Alternative Name: GP; GP1; GP2; Shed GP; Second secreted glycoprotein; small secreted glycoprotein; spike glycoprotein

Tag Line: A humanized monoclonal antibody that targets the Ebola virus envelope glycoprotein

Category: GM-CSF

Host: XtenCHO cells

Isotype: IgG1

Species Reactivities: Ebola Virus

Immunogen Sequence: FALSE

Accession #: Q05320

Gene ID: 911829

Appearance: Liquid

Form: Humanized IgG1

Concentration:

Formulation: In PBS, pH 7.5

Purification: FALSE

Application: FALSE

Positive Control:

Application And Usages:

Country of Animal Origin: USA

Country of Manufacture: USA

Usage: For Research Use Only! Not to be used in humans.

Handling: The antibody solution should be gently mixed before use.

Western Blot Verified: FALSE

Immunocytochemistry Verified:

Immunofluorescence Verified: FALSE

Immunoprecipitation Verified: FALSE

FACS Verified:

ELISA Verified: FALSE

ChIP Verified: FALSE

Dot Blot Verified: FALSE

Flow Cytometry Verified: FALSE